Current status and future prospects for human papillomavirus vaccines
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Hyoung Jin | - |
dc.contributor.author | Kim, Hong-Jin | - |
dc.date.available | 2019-03-08T07:58:10Z | - |
dc.date.issued | 2017-09 | - |
dc.identifier.issn | 0253-6269 | - |
dc.identifier.issn | 1976-3786 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/4025 | - |
dc.description.abstract | Cervical cancer is the fourth most frequent cancer among women worldwide. Human papillomaviruses (HPVs) cause almost all cervical cancers in low-income countries. Three prophylactic HPV virus-like particle-based vaccines have been licensed to date, and they have all shown high efficacy and reliable safety profiles. However, isolated safety issues have resulted in a reluctance to use these vaccinations. In addition, the high prices of the vaccinations have caused the inequitable distribution of the vaccine: the prices are unaffordable for low-income countries. Meanwhile, great effort has been put into the development of therapeutic HPV vaccines, including protein/peptide-, live vector-, DNA- and cell-based vaccines. These new vaccines have considerable therapeutic potential but limited practical use. The development of immune checkpoint inhibitors and personalized immunotherapy remain challenges for future study. In this article, the current status of the licensed vaccines, therapeutic HPV vaccines and biosimilars, and new platforms for HPV vaccines, are reviewed, and safety issues related to the licensed vaccines are discussed. In addition, the prospects for HPV vaccines are considered. | - |
dc.format.extent | 14 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | PHARMACEUTICAL SOC KOREA | - |
dc.title | Current status and future prospects for human papillomavirus vaccines | - |
dc.type | Article | - |
dc.identifier.doi | 10.1007/s12272-017-0952-8 | - |
dc.identifier.bibliographicCitation | ARCHIVES OF PHARMACAL RESEARCH, v.40, no.9, pp 1050 - 1063 | - |
dc.identifier.kciid | ART002263790 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000411863500005 | - |
dc.identifier.scopusid | 2-s2.0-85029000213 | - |
dc.citation.endPage | 1063 | - |
dc.citation.number | 9 | - |
dc.citation.startPage | 1050 | - |
dc.citation.title | ARCHIVES OF PHARMACAL RESEARCH | - |
dc.citation.volume | 40 | - |
dc.type.docType | Review | - |
dc.publisher.location | 대한민국 | - |
dc.subject.keywordAuthor | Prophylactic vaccine | - |
dc.subject.keywordAuthor | Therapeutic vaccine | - |
dc.subject.keywordAuthor | Immunotherapy | - |
dc.subject.keywordAuthor | Immune checkpoint | - |
dc.subject.keywordAuthor | Biosimilar | - |
dc.subject.keywordPlus | VIRUS-LIKE PARTICLES | - |
dc.subject.keywordPlus | HPV-16/18 AS04-ADJUVANTED VACCINE | - |
dc.subject.keywordPlus | INTRAEPITHELIAL NEOPLASIA 2/3 | - |
dc.subject.keywordPlus | AUTOIMMUNE ADVERSE EVENTS | - |
dc.subject.keywordPlus | CERVICAL-CANCER VACCINES | - |
dc.subject.keywordPlus | ADOPTIVE CELL TRANSFER | - |
dc.subject.keywordPlus | MINOR CAPSID PROTEIN | - |
dc.subject.keywordPlus | HPV VACCINE | - |
dc.subject.keywordPlus | DNA VACCINE | - |
dc.subject.keywordPlus | LISTERIA-MONOCYTOGENES | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Medicinal | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.